Increased pancreatic cancer risk following radiotherapy for testicular cancer

British Journal of Cancer

Volumn 115, Issue 7, 2016, Pages 901-908

  Hauptmann, Michael ^a   Johannesen, Tom BØrge ^b   Gilbert, Ethel S ^c   Stovall, Marilyn ^d   Van Leeuwen, Flora E ^a   Rajaraman, Preetha ^c   Smith, Susan A ^d   Weathers, Rita E ^d   Aleman, Berthe M P ^a   Andersson, Michael ^e   Curtis, Rochelle E ^c   Dores, Graca M ^c   Fraumeni, Joseph F ^c   Hall, Per ^f   Holowaty, Eric J ^g   Joensuu, Heikki ^h   Kaijser, Magnus ^f   Kleinerman, Ruth A ^c   Langmark, FrØydis ^b   Lynch, Charles F ⁱ   Pukkala, Eero ^j,k   Storm, Hans H ^l   Vaalavirta, Leila ^h   Van Den Belt Dusebout, Alexandra W ^a   Morton, Lindsay M ^c   Fossa, Sophie D ^m   Travis, Lois B ⁿ   more..

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b CANCER REGISTRY OF NORWAY   (Norway)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e Mental Health Center Glostrup   (Denmark)

^f KAROLINSKA INSTITUTE   (Sweden)

^g UNIVERSITY OF TORONTO   (Canada)

^h HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

ⁱ UNIVERSITY OF IOWA   (United States)

^j FINNISH CANCER REGISTRY   (Finland)

^k TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^l DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^m OSLO UNIVERSITY HOSPITAL   (Norway)

ⁿ UNIVERSITY OF INDIANAPOLIS   (United States)

more..

Author keywords

chemotherapy; logistic regression; pancreatic cancer; radiotherapy; testicular cancer

Indexed keywords

ALKYLATING AGENT; PLATINUM DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVOR; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; PANCREAS CANCER; PRIMARY TUMOR; PRIORITY JOURNAL; RADIATION EXPOSURE; RADIATION INDUCED NEOPLASM; RADIATION RESPONSE; RADIOTHERAPY DOSAGE; SECOND CANCER; SEMINOMA; TESTIS CANCER; TESTIS NONSEMINOMA CANCER; ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; CASE CONTROL STUDY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEOPLASMS, RADIATION-INDUCED; NEOPLASMS, SECOND PRIMARY; ORGANS AT RISK; PANCREAS; PANCREATIC NEOPLASMS; RISK; TESTICULAR NEOPLASMS; YOUNG ADULT;

ADULT; AGED; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, RADIATION-INDUCED; NEOPLASMS, SECOND PRIMARY; ORCHIECTOMY; ORGANS AT RISK; PANCREAS; PANCREATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RISK; TESTICULAR NEOPLASMS; YOUNG ADULT;

EID: 84986556259     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2016.272     Document Type: Article

References (42)

1. Arvold ND, Catalano PJ, Sweeney CJ, Hoffman KE, Nguyen PL, Balboni TA, Fossa SD, Travis LB, Beard CJ. (2012). Barriers to the implementation of surveillance for stage I testicular seminoma. Int J Radiat Oncol Biol Phys 84(2): 383-389
2. Biggs ML, Schwartz SM. (2007). Cancer of the testis. In SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics, Ries LA, Young JL, Keel GE, Eisner MP, Lin YD, Horner MJ (eds). National Cancer Institute, SEER Program, NIH Pub. No. 07-6215: Bethesda, MD.
3. Breslow NE, Day NE. (1980). Statistical Methods in Cancer Research, Vol. 1. The Analysis of Case-Control Studies. International Agency for Research on Cancer: Lyon, France
4. Brunton LL, Chabner BA, Knollmann BC (eds). (2011). Goodman and Gilman's The Pharmacological Basis of Therapeutics, 12th edn. McGraw Hill
5. Carr ZA, Kleinerman RA, Stovall M, Weinstock RM, Griem ML, Land CE. (2002). Malignant neoplasms after radiation therapy for peptic ulcer. Radiat Res 157: 668-677
6. Chia VM, Quraishi SM, Devesa SS, Purdue MP, Cook MB, McGlynn KA. (2010). International trends in the incidence of testicular cancer, 1973-2002. Cancer Epidemiol Biomarkers Prev 19(5): 1151-1159
7. Comprehensive Cancer Center Netherlands. (2014). Kankerzorg in beeld -rapportage testiscarcinoom. Available at: https://www.iknl.nl/docs/defaultsource/KIB-rapportages/portfolio-kib-Testiscarcinoom.pdf?.sfvrsn=2[in Dutch].
8. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS, Jemal A. (2010). Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 64(4): 252-271
9. Dores GM, Curtis RE, Van Leeuwen FE, Stovall M, Hall P, Lynch CF, Smith SA, Weathers RE, Storm HH, Hodgson DC, Kleinerman RA, Joensuu H, Johannesen TB, Andersson M, Holowaty EJ, Kaijser M, Pukkala E, Vaalavirta L, Fossa SD, Langmark F, Travis LB, Fraumeni Jr. JF, Aleman BM, Morton LM, Gilbert ES. (2014). Pancreatic cancer risk after treatment of Hodgkin lymphoma. Ann Oncol 25(10): 2073-2079
10. Einhorn LH, Donohue J. (1977). Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87(3): 293-298
11. Engholm G, Ferlay J, Christensen N, Bray F, Gjerstorff ML, Klint A, Kotlum JE, Olafsdottir E, Pukkala E, Storm HH. (2010). NORDCAN - A Nordic tool for cancer information, planning, quality control and research. Acta Oncol 49(5): 725-736
12. Garner MJ, Turner MC, Ghadirian P, Krewski D. (2005). Epidemiology of testicular cancer: an overview. Int J Cancer 116(3): 331-339
13. Gooley TA, Leisenring W, Crowley J, Storer BE. (1999). Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 18(6): 695-706
14. Halperin EC, Brady LW, Perez CA, Wazer De. (2013). Perez & Brady's Principles and Practice of Radiation Oncology, 6th edn. Wolters Kluwer: Amsterdam, The Netherlands
15. Hoffman KE, Chen MH, Punglia RS. (2008). Influence of year of diagnosis, patient age, and sociodemographic status on recommending adjuvant radiation treatment for stage I testicular seminoma. J Clin Oncol 26: 3937-3942
16. Horwich A, Fossa S, Huddart R, Dearnaley DP, Stenning S, Aresu M, Bliss JM, Hall E. (2014). Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma. Br J Cancer 110: 256-263
17. International Agency for Research on Cancer. (2004). Tobacco smoke and involuntary smoking. Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 83. World Health Organization: Lyon, France
18. Jones WG, Fossa SD, Mead GM, Roberts JT, Sokal M, Horwich A, Stenning SP. (2005). Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol 23(6): 1200-1208
19. Kohut Jr. RM, Minnillo BJ, Kypriotakis G, Abouassaly R, Zhu H. (2014). Changes in adjuvant therapy utilization in stage I seminoma: are they enough to prevent overtreatment?. Urology 84(6): 1319-1324
20. Kollmannsberger C, Hartmann JT, Kanz L, Bokemeyer C. (1999). Therapy-related malignancies following treatment of germ cell cancer. Int J Cancer 83: 860-863
21. Lau MK, Davila JA, Shaib YH. (2010). Incidence and survival of pancreatic head and body and tail cancers: a population-based study in the United States. Pancreas 39(4): 458-462
22. Maisonneuve P, Lowenfels AB. (2015). Risk factors for pancreatic cancer: a summary review of meta-Analytical studies. Int J Epidemiol 44(1): 186-198
23. McGlynn KA, Devesa SS, Sigurdson AJ, Brown LM, Tsao L, Tarone RE. (2003). Trends in the incidence of testicular germ cell tumors in the United States. Cancer 97(1): 63-70
24. National Comprehensive Cancer Network (NCCN). (2013). Clinical Practice Guidelines in Oncology. Testicular Cancer (Version 1). Available at: www.NCCN.org
25. Perez CA, Brady LW, Halperin EC. (2008). Perez & Brady's Principles and Practice of Radiation Oncology, 5th edn. pp 1574-1575. Lippincott Williams & Wilkins: Philadelphia, PA.
26. Preston DL, Lubin JH, Pierce DA, McConney ME. (1993). Epicure User's Guide. HiroSoft International Corporation: Seattle, WA.
27. Robinson D, Moller H, Horwich A. (2007). Mortality and incidence of second cancers following treatment for testicular cancer. Br J Cancer 96: 529-533
28. Ryan DP, Hong TS, Bardeesy N. (2014). Pancreatic adenocarcinoma. N Engl J Med 371(11): 1039-1049
29. Schmoll HJ, Jordan K, Huddart R, Laguna MP, Horwich A, Fizazi K, Kataja V. ESMO Guidelines Working Group. (2009). Testicular seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4): 83-88
30. Siegel RL, Miller KD, Jemal A. (2015). Cancer statistics, 2015. CA Cancer J Clin 65(1): 5-29
31. Stovall M, Weathers R, Kasper C, Smith SA, Travis L, Ron E, Kleinerman R. (2006). Dose reconstruction for therapeutic and diagnostic radiation exposures: use in epidemiological studies. Radiat Res 166: 141-157
32. Teepen JC, De Vroom SL, Van Leeuwen FE, Tissing WJ, Kremer LC, Ronckers CM. (2016). Risk of subsequent gastrointestinal cancer among childhood cancer survivors: a systematic review. Cancer Treat Rev 43: 92-103
33. Teiblum S, Thygesen LC, Johansen C. (2009). Sixty-one years of pancreatic cancer in Denmark from 1943 to 2003: a nationwide study. Pancreas 38(4): 374-378
34. Travis LB, Curtis RE, Storm H, Hall P, Holowaty E, Van Leeuwen FE, Kohler BA, Pukkala E, Lynch CF, Andersson M, Bergfeldt K, Clarke EA, Wiklund T, Stoter G, Gospodarowicz M, Sturgeon J, Fraumeni Jr. JF, Boice JD Jr. (1997). Risk of second malignant neoplasms among long-Term survivors of testicular cancer. J Natl Cancer Inst 89: 1429-1439
35. Travis LB, Hauptmann M, Gaul LK, Storm HH, Goldman MB, Nyberg U, Berger E, Janower ML, Hall P, Monson RR, Holm LE, Land CE, Schottenfeld D, Boice Jr. JD, Andersson M. (2003). Site-specific cancer incidence and mortality after cerebral angiography with radioactive thorotrast. Radiat Res 160(6): 691-706
36. Travis LB, Fossa SD, Schonfeld SJ, McMaster ML, Lynch CF, Storm H, Hall P, Holowaty E, Andersen A, Pukkala E, Andersson M, Kaijser M, Gospodarowicz M, Joensuu T, Cohen RJ, Boice Jr. JD, Dores GM, Gilbert ES. (2005). Second cancers among 40, 576 testicular cancer patients: focus on long-Term survivors. J Natl Cancer Inst 97(18): 1354-1365
37. Van den Belt-Dusebout AW, Aleman BM, Besseling G, De Bruin ML, Hauptmann M, Van t Veer MB, De Wit R, Ribot JG, Noordijk EM, Kerst JM, Gietema JA, Van Leeuwen FE. (2009). Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy.Int J Radiat Oncol Biol Phys 75(5): 1420-1429
38. Van Leeuwen FE, Stiggelbout AM, Van den Belt-Dusebout AW, Noyon R, Eliel MR, Van Kerkhoff EH, Delemarre JF, Somers R. (1993). Second cancer risk following testicular cancer: a follow-up study of 1909 patients. J Clin Oncol 11: 415-424
39. Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L, Kunkler I. (2007). Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 8(9): 784-796
40. Vossen CY, Horwich A, Daugaard G, Van Poppel H, Osanto S. (2012). Patterns of care in the management of seminoma stage I: results from a European survey. BJU Int 110(4): 524-531
41. Weiss HA, Darby SC, Doll R. (1994). Cancer mortality following X-ray treatment for ankylosing spondylitis. Int J Cancer 59(3): 327-338
42. Yu HY, Madison RA, Setodji CM, Saigal CS. (2009). Quality of surveillance for stage I testis cancer in the community. J Clin Oncol 27: 4327-4332